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Abstract
Background: Despite encouraging reports on the efficacy of intravenous
immunoglobulin (IVIg) in antiphospholipid syndrome, the clinical value of this
treatment is not well established, and most of the data are based on case reports
and small series of patients.
Observation:We describe the significant improvement of leg ulcers with IVIg in
a 61-year-old female, with diabetes mellitus, venous peripherical insufficiency
and secondary antiphospholipid syndrome to systemic lupus erythematosus.
Conclusion: This case illustrates a rare cause of leg ulcers and documents that
IVIg may be an effective adjuvant treatment in the management of selected patients
with antiphospholipid syndrome when conventional strategies using subcutaneous
heparin and low-dose aspirin are insufficient. (J Dermatol Case Rep. 2014; 8(2): 38-41)
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Introduction
Lower extremity ulcers are an infrequent but disabling
complication of long-standing connective tissue diseases.
They occur more commonly in patients with these diseases
than in general population.1 Although these lesions have hi-
storically been attributed to vasculitis, it is now recognized
that inflammatory vessel injury accounts for fewer than 20%
of ulcers in connective tissue disease.1 The pathogenesis
still remains incompletely understood. It is known that in-
flammation serves as a necessary link between the observed
procoagulant phenotype and actual thrombus development.2
In systemic lupus erythematosus, ulcers were seen in 5,6%
of patients.1
Antiphospholipid syndrome (APS) is an acquired autoim-
mune thrombophilia that produces significant morbidity and
mortality.1,3,4 Its diagnosis requires the presence of antipho-
spholipid antibodies (aPL) and clinical manifestations that
include thrombotic phenomena and/or recurrent miscarria-
ges.1,3,4 It can be either primary or secondary to an under-
lying condition, most commonly systemic lupus erythema-
tosus (SLE).4 Clinical manifestations are varied.1,3,4,5 The most
frequent skin lesions in patients with APS are livedo reticu-
laris and skin ulcers.3,4,5,6
The authors describe the resolution of leg ulcers in APS se-
condary to SLE treated with intravenous immunoglobulin (IVIg).
Case report
Female, 61-year-old, presented with spontaneous, sudden
onset, painful, rapidly enlarging leg ulcers, lasting for few
days. The patient had one spontaneous abortion. Systemic
erythematosus lupus were diagnosed 18 years before, ba-
sed on cutaneous, hematologic and immunologic disorders.
She had a medical history of polyarthralgia, with early mor-
ning stiffness, of the cervical, knee and shoulder joints, with
intermittent arthritis of the interphalangeal joints and less
frequently of the feet, not documented in radiological exams.
She had recurrent epistaxis and hematomas due to thrombo-
cytopenia for several years, with a minimum platelet count
of 44.109/L (normal levels superior to 150.109/L), leucope-
nia 3.8.109/L (in 1994, normal levels superior to 4.5.109/L).
The patient also had in the past ANAs 1/100 (speckled pattern),
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and showed an ulcer with a mixed inflammatory infiltrate
with microthrombus in dermal vessels adjacent to the area
of ulceration with no inflammatory component in the vascu-
lar wall. These findings, supported by clinical features, were
consistent with APS (Fig. 2). Doppler sonography was done
and revealed parietal arterial calcifications, with no signifi-
cant stenosis. Venous Doppler sonography revealed relapse
of the right sapheno-femoral junction, varicoses in the in-
ternal face of the right thigh and leg.
Concomitantly to hydroxychloroquine (400 mg daily) and
high dosis of corticosteroids (60 mg of prednisolone), the
patient began low-weight-heparin (enoxaparin 60mg sub-
cutaneously initially, tapered to 40mg/day), switched after
to warfarin (5 to 6,25 mg/day). There was initially poor com-
pliance of the patient, namely in taking regularly the antico-
agulation drugs because she referred occasional bleeding of
the legs ulcers that led to uncontrolled INR (between 1-2)
and clinical aggravation. Despite 4 months of treatment and
several local treatments (charcoal alginate dressings, sodium
carboxymethyl cellulose, activated charcoal dressing, colla-
genase and povidone-iodine polymer), the results were unsa-
tisfactory.
Then, the patient started treatment with IVIg 1 g/kg daily,
every four weeks in two consecutive days. Amarked improvement
anti-SSA positive, anti-DNA 776UI/ml (superior to 300 UI/ml),
anticardiolipin antibody (aCL)-IgG: 17,68 GPL/ml (≥ 12
GPL/ml) and aCL-IgM negative. The patient presented pho-
tosenssibility, malar erythema, due to lupus erythematosus
confirmed by punch biopsy and non-scarring diffuse alope-
cia. There were no others systemic involvement. The patient
was treated with NSAIDs, cycles of systemic corticostero-
ids, resorchin and posteriorly hydroxychloroquine during
the exacerbations of the arthralgias and the cutaneous chan-
ges. The patient also presented diabetes mellitus for 21
years, treated with insulin since 8 years, high blood pres-
sure for 21 years treated initially with captopril and actual-
ly with bisoprolol and, venous peripherical insufficiency with
right saphenectomy.
When she came to our department, she presented exten-
sive, deep and sharply marginated, with noninflammatory
periphery skin ulcers of both legs. She had a 25 cm-longest
diameter on the lateral face of the right leg, a smaller ulcer
on the lateral and posterior face of the left leg, and the smal-
lest one in the dorsum of the foot (Fig. 1).
Complete blood analyses were performed: antinuclear an-
tibodies (ANA): 1/160, speckled pattern, aCL-IgM: 43,7 MPL/ml
(≥ 12 GPL/ml), aCL-IgG: 98,1 GPL/ml (≥ 12 GPL/ml) with no
others laboratory changes. A punch biopsy was performed
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Figure 1
Right leg ulcer A) before IVIG, B) after
the first infusion and C) completely
healed.
Left leg ulcer D) before IVIG, E) after
the fifth infusion and F) completely
healed.
of associated autoimmune diseases and other risk factors
for venous or arterial thrombosis.10
The antiplatelet therapy such as low-aspirin plus prophy-
lactic unfractionated and/or low-molecular-weight heparin
(LMWH) is usually chosen as first-line treatment.3,6,11 Wide-
spread cutaneous lesions are considered to be major throm-
botic events and their recommended treatment is long-term-
high-intensity warfarin (INR≥3).6,10,11,13 Currently, new ge-
nerations of anticoagulants like dabigatran etexilate (prada-
xa) and rivaroxaban (xarelto) are available.12
Major bleeding associated with oral anticoagulant thera-
py is low.13 However, in patients with risk for bleeding, as
the ulcers of our patient or patients with severe thrombo-
cytopenia, which is a common laboratory manifestation of
APS (frequently due to the presence of aPL), IVIg can be an
adjuvant option.11
Several immunosuppressive treatments are effective in
improving platelet count as rituximab and more recently be-
limumab.11 Therapy with sildenafil, cyclosporine A, plasma-
pheresis, were also tried with good results but are only li-
mited to anecdotal cases.13,14,15 Hydroxychloroquine and
low-dose prednisolone appear to be useful when added to
standard therapy in refractory APS. Because hydroxychloro-
quine has also antiplatelet effects and reduce the risk of
thrombosis, it is useful in APS especially in APS secondary
to SLE as the case of our patient.9 However, long-term an-
ticoagulation is frequently required.6,14
Of patients with skin involvement, 40% will develop mul-
tisystemic thombotic events.
Recurrence remains frequent despite the use of oral anti-
coagulants. Patients with APS and triple positivity for aPL
are at high risk of developing future thromboembolic events.10
IVIg is beneficial and carries a good safety profile in treat-
ment of SLE11,18,19,20 and other autoimmune diseases as APS.
IVIG is usually safer than immunosuppressive agents19 but
it should be noted that a few complications may accompa-
ny its use, among the most frequent are rash, headache and
arthralgia. The beneficial effects of IVIG on overall APS ac-
tivity are usually prompt within a few days, but they are
often of limited duration.19 In our patient, we observed that
the quicker and bigger improvement of the ulcers was al-
ways promptly (days) after the administration of Immuno-
globulin. IVIG has the advantage to both inhibits the anti-
phospholipid antibodies, and probably decreases their fur-
ther production.1 The report by Sherer et al contributes to
understand that in certain patient subgroups IVIG might
have an additive effect to anticoagulation.19 The detrimen-
tal effects of aPL should also be attributes to mechanisms
other than thrombosis. The advantage of using IVIG over
conventional therapies or in combination is that IVIG has
not been found to increase the risk of opportunistic infec-
tions and hence, can spare steroids or other immunosup-
pressive treatments.20 This advantage was also particularly
appreciated in this patient due to her immunodeficiency.
This adjuvant therapeutical option also avoids bleeding risks.
Although experience remains limited and uncontrolled,
intravenous immunoglobulin (IVIg) therapy probably has
a place in the management of selected patients with APS
when conventional strategies using subcutaneous heparin
was noticed promptly after the first infusion leading to smal-
ler and more superficial ulcers. Three months after, the right
leg ulcer closed and the left leg ulcer had a significant im-
provement (Fig. 1).
The patient also began concomitantly with the third ad-
ministration of IVIg, azathioprin (50 mg/day up to 150 mg/day)
in order to accelerate the repitelizing of the ulcers. She com-
pleted eight cycles of IVIg and continued hydroxychloroqu-
ine, the anticoagulation treatment and lower dosage of im-
munossupressive treatment (systemic steroids progressive-
ly tapered to 20 mg/day and azathioprin tapered until stop-
ping it. After 3 years of hydroxychloroquine, cycles of cor-
ticosteroids (between 20-40 mg/day), hyperbaric oxygen
therapy in 2010 (60 sessions of 90 minutes, 2,5 atmosphe-
re absolute), a better compliance with anticoagulation tre-
atment (but frequently with infra-therapeutic levels with INR
under values of 2), and local wound care (mainly povidone-
iodine polymer and activated charcoal dressing), the ulcers
healed completely. The patient is still under hydroxychloro-
quine and warfarin.
Discussion
The dermatologic manifestations of APS are frequently the
presenting feature of the syndrome3,6 and leg ulcers are
considered to be among their most frequent manifestations
with characteristically poor response to treatment.7,8 It is
known that 30 to 50% of the patients with systemic lupus
erythematosus will develop APS. Our patient has developed
APS after 18 years of the diagnosis of SLE. The precise me-
chanisms responsible for thrombosis in these patients re-
mains unclear.9
Therapy for dermatologic lesions due to APS remains em-
prirical due to the scarcity of cases.6 The management of
these lesions depends on their clinical aggressiveness but
the overall clinical situation must be considered.6 The the-
rapeutic decisions must consider laboratory profile, the presence
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Figure 2
Histopathology of the ulcer area. Microthrombus without in-
flammatory component of the vascular wall (HEx100).
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and low-dose aspirin have failed.11 This case documented
that IVIg may be an effective adjuvant treatment of leg ulcers
due to secondary APS.
Preventing the recurrence of skin lesions in APS depends
not only on their severity, but also on the features of the di-
sease. There are no data concerning the frequency of recur-
rence of skin vessels thrombosis.6 Duration of anticoagula-
tion therapy is controversial and some authors recommend
lifelong anticoagulation therapy.13 It is important to remove
or reduce risk factors as stop smoking and avoid estrogen-
containing-pills.
More data should be obtained in order to decide the opti-
mal treatment of this syndrome which is still unclear.
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